Antares Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>AP</div>
ATRS -- USA Stock  

USD 3.84  0.06  1.54%

Antares Pharma Receivables Turnover is relatively stable at the moment as compared to the past year. Antares Pharma reported last year Receivables Turnover of 5.27. As of 03/02/2021, Inventory Turnover is likely to grow to 5.66, while Revenue Per Employee is likely to drop slightly above 699.7 K. The underlying reasoning behind this short post is to sum up Antares as an investment oportunity for April. We will discuss why recent Antares Pharma price moves suggest a bounce in April.
Published over a month ago
View all stories for Antares Pharma | View All Stories
Are Antares (NASDAQ:ATRS) retail investors starting to hold back?
On a scale of 0 to 100, Antares Pharma holds a performance score of 14. The firm shows a Beta (market volatility) of 0.5858, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Antares's beta means in this case. As returns on the market increase, Antares Pharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Antares Pharma will be expected to be smaller as well. Although it is vital to follow Antares Pharma historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for Antares Pharma, which you can use to evaluate the performance of the firm. Please makes use of Antares Pharma jensen alpha, potential upside, as well as the relationship between the Potential Upside and accumulation distribution to make a quick decision on whether Antares Pharma price patterns will revert.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Antares Pharma. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Antares Pharma

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Antares Pharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Antares Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Antares Pharma. Your research has to be compared to or analyzed against Antares Pharma's peers to derive any actionable benefits. When done correctly, Antares Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Antares Pharma.

How important is Antares Pharma's Liquidity

Antares Pharma financial leverage refers to using borrowed capital as a funding source to finance Antares Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Antares Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Antares Pharma's total debt and its cash.

How Antares utilizes its cash?

To perform a cash flow analysis of Antares Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Antares Pharma is receiving and how much cash it distributes out in a given period. The Antares Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Antares Pharma Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Antares Pharma reported last year Net Cash Flow from Operations of 21.32 Million

A Deeper Perspective

Antares Pharma currently demonstrates below-average downside deviation. It has Information Ratio of 0.22 and Jensen Alpha of 0.67. However, we advise investors to further question Antares Pharma expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Antares Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Antares Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Returns Breakdown

Return on Investment1.21
Return on Assets(0.0211)
Return on Equity(0.0546)
Return Capital0.0165
Return on Sales0.0149

Will Antares Pharma continue to go crazy?

Antares Pharma latest total risk alpha advances over 0.4. Antares Pharma currently demonstrates below-average downside deviation. It has Information Ratio of 0.22 and Jensen Alpha of 0.67. However, we advise investors to further question Antares Pharma expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Antares Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Antares Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Antares Pharma

While other companies within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Antares Pharma may offer a potential longer-term growth to retail investors. To conclude, as of the 2nd of March 2021, we believe that at this point, Antares Pharma is undervalued with low chance of bankruptcy within the next 2 years. Our concluding buy-sell recommendation on the enterprise is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Antares Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com